Crovalimab Loading and Maintenance Dosing for GBS Nerve Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Guillain-Barré Syndrome (GBS) such as intravenous immunoglobulin (IVIg) and plasma exchange have limited efficacy in improving long-term outcomes, and there is a need for more effective complement inhibition strategies to prevent nerve damage.
Innovation Solution
A dosage regimen involving an initial intravenous loading dose of 1500 mg of the anti-C5 antibody Crovalimab followed by subcutaneous maintenance doses of 340 mg at specific intervals to maintain effective anti-C5 antibody concentration, potentially combined with IVIg, to inhibit complement activation and prevent nerve damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If traditional treatments (IVIg or plasma exchange) are used for GBS, then treatment accessibility is improved, but long-term outcome improvement is limited
Solution Approach 1:
The patent changes the therapeutic parameter from non-specific immunomodulation (IVIg) or plasma removal (plasma exchange) to specific complement C5 inhibition using crovalimab antibody, thereby improving long-term outcomes while maintaining treatment accessibility
Solution Approach 2:
The patent replaces the mechanical/physical processes of plasma exchange with a biochemical mechanism (complement inhibition) that specifically targets the pathophysiological pathway of GBS, achieving better neurological recovery without the invasiveness of plasma exchange
2Reliability
If high dose anti-C5 antibody is administered to ensure effective complement inhibition, then therapeutic efficacy is improved, but treatment complexity and dosing regimen complexity increases
Solution Approach 1:
The patent applies a loading dose strategy where a high initial dose (1500 mg IV) is administered first to rapidly achieve therapeutic antibody levels and ensure effective complement inhibition, followed by lower maintenance doses, thereby simplifying the overall treatment approach while maintaining efficacy
Solution Approach 2:
The patent establishes a periodic dosing schedule with specific intervals (initial dose at day 1, subsequent doses at days 8, 15, 22, etc.) that maintains therapeutic antibody levels over time, converting the complexity of continuous dosing into a simplified periodic regimen
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The regimen effectively maintains therapeutic anti-C5 antibody levels, providing potential long-term nerve protection and improved motor function in GBS patients, enhancing treatment efficacy beyond traditional therapies.
Implementation Method 1
Crovalimab is a novel humanized anti-C5 monoclonal antibody which binds to complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9 (MAC)
Implementation Method 2
The half-life of IVIg and crovalimab are dependent on the recycling by FcRn receptors in the endosome
Data Source
AI summary
The present invention relates to a dosage and administration regimen of anti-C5 antibodies, particularly of the anti-C5 antibody Crovalimab, for use in a method of treating or preventing GBS in a subject. The dosage and treatment regimen of the present invention include the administration of an anti-C5 antibody, preferably of the anti-C5 antibody Crovalimab, with loading dose followed by the administration of (a) maintenance dose(s) of the anti-C5 antibody to the subject, wherein the initial administered loading dose is intravenously given to the subject and the maintenance doses are subcutaneously administered in a lower dosage as the intravenously administered loading dose.